Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Thoracic Oncology

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0000000000000141PMID 24662454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?

  2013cited by this paper
• EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

  2012cited by this paper
• Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

  2012influential reference
• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

  2012influential reference
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819

  2012influential reference
• Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target

  2012cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

  2011cited by this paper
• Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

  2011influential reference
• Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

  2010cited by this paper
• Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas

  2010cited by this paper
• Clonal evolution in cancer

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• EGFR T790M mutation: a double role in lung cancer cell survival?

  2009influential reference
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

  2009cited by this paper
• Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

  2008cited by this paper
• Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

  2007cited by this paper
• Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer

  2006cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper

• Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.

  2025cites this paper
• Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decades.

  2025cites this paper
• Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort

  2024cites this paper
• Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancer

  2023cites this paper
• Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report

  2022cites this paper
• Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes

  2022cites this paper
• Ge fi tinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR – Intergenic Region ( SEC61G ) Fusion and EGFR Ampli fi cation

  2021cites this paper
• A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

  2021cites this paper
• PO2RDF: representation of real-world data for precision oncology using resource description framework

  2021cites this paper
• Gefitinib combined with cetuximab for the treatment of lung adenocarcinoma harboring the EGFR-IGR (SEC61G) fusion and EGFR amplification.

  2021cites this paper
• Antibody-Based Immunotoxins for Colorectal Cancer Therapy

  2021cites this paper
• Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer

  2021influential citation
• A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients

  2020cites this paper
• Lower Respiratory Tract

  2020cites this paper
• Clinical significance of selected genes variations using targeted deep sequencing in non-small-cell lung cancer

  2019cites this paper
• EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

  2019cites this paper
• A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

  2019cites this paper
• Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition

  2019cites this paper
• Synthesis and evaluation of 64Cu-radiolabeled NOTA-cetuximab (64Cu-NOTA-C225) for immuno-PET imaging of EGFR expression

  2019cites this paper
• Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

  2018cites this paper
• Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma

  2018cites this paper
• Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma

  2018cites this paper
• UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5 INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA

  2018cites this paper
• Evaluation of affibody charge modification identified by synthetic consensus design in molecular PET imaging of epidermal growth factor receptor.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization

  2018cites this paper
• Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

  2018cites this paper
• Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

  2018influential citation
• Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

  2018cites this paper
• Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study

  2018cites this paper
• Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

  2017cites this paper
• Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.

  2017cites this paper
• Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations

  2017cites this paper
• Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma

  2017cites this paper
• Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol

  2017cites this paper
• Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer.

  2017cites this paper
• First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

  2017cites this paper
• The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis

  2017cites this paper
• Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

  2017influential citation
• Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer types

  2017cites this paper
• Pan-cancer study of heterogeneous RNA aberrations

  2017cites this paper
• versus a

  2017cites this paper
• Necitumumab in squamous non-small-cell lung cancer: how to move forward?

  2016cites this paper
• EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy

  2016cites this paper
• A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.

  2016cites this paper
• Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC

  2016cites this paper
• Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity

  2016cites this paper
• Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

  2016influential citation
• Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer

  2016cites this paper
• Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

  2015cites this paper
• Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway

  2015cites this paper
• Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.

  2015cites this paper
• Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma

  2015cites this paper
• Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update

  2015cites this paper
• Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

  2015influential citation
• Inhibitory Effects of Hybrid Liposomes on the Growth of Non-small Cell Lung Carcinoma Cells and Anti-invasive Activity by Ceramide Generation without any Drugs

  2015cites this paper
• Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer

  2014cites this paper
• Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry

  2014influential citation
• Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab

  2014cites this paper
• of Pharmacology

  year unknowncites this paper